Explore

Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer

Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer

Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer
Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors
Trendline Trendline
Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones
Trendline Trendline
Brenus Pharma's STC-1010 Receives FDA IND Approval for Colorectal Cancer

Brenus Pharma's STC-1010 Receives FDA IND Approval for Colorectal Cancer

Brenus Pharma's STC-1010 Receives FDA IND Approval for Colorectal Cancer